Clinical trials: Eye Cancer, Intraocular Melanoma
Uveal Melanoma, Liver Metastases
Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF
Patients with uveal melanoma metastatic to the liver will be treated with embolization of the hepatic artery every 4 weeks. GM-CSF (granulocyte-macrophage colony simulating factor) or normal saline will be injected into one of…
- Trial name
- NCT00661622
- Testing
- GM-CSF, Embolization
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Uveal Melanoma
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
- Trial name
- NCT06070012
- Testing
- Tebentafusp
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Diwakar Davar
Uveal Melanoma
New Biopsy Technique for Uveal Melanoma
This pilot study intends to investigate a new biopsy technique that will decrease the incidence of tumor cells in the biopsy tract.
- Trial name
- NCT01924923
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Greater Houston Retina Research
Metastatic Uveal Melanoma
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
This research study is investigating Binimetinib and Belinostat in participants with metastatic uveal melanoma. The research study will test the study drugs to see if the combination of binimetinib and belinostat can make tumors…
- Trial name
- NCT05170334
- Testing
- Binimetinib, Belinostat
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Uveal Melanoma, Ocular Melanoma
A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma
The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma.
- Trial name
- OCULE-01 (NCT06717126)
- Testing
- roginolisib, Investigator choice of standard therapy
- Where
- 16 sites in Italy, Spain and 1 more
- Volunteers
- 85 people
- Sponsor
- iOnctura
Ocular Melanoma
Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma
The reference treatment of ocular melanoma is a conservative treatment by proton therapy. Its goal is to treat the tumor while preserving the eyeball and visual acuity.
- Trial name
- PROTECT (NCT03172299)
- Testing
- Aflibercept Injection, False injection
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Ocular Melanoma
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
STA-9090, a synthetic small molecule, demonstrates significant activity for down-regulating Heat Shock Protein 90 or Hsp90 levels.
- Trial name
- NCT01200238
- Testing
- STA-9090
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Dana-Farber Cancer Institute
Intraocular Melanoma
Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma
RATIONALE: Studying samples of bone marrow and blood from patients with cancer may help doctors find out the extent of disease. PURPOSE: This research study is collecting bone marrow and blood samples from patients with…
- Trial name
- NCT00897624
- Testing
- gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis
- Volunteers
- 15 people
- Sponsor
- Institut Curie
Extraocular Extension Melanoma, Recurrent Intraocular Melanoma
Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 may be a more effective treatment for metastatic melanoma of the eye.
- Trial name
- NCT00020475
- Testing
- gp100 antigen, interleukin-2, MART-1 antigen
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Uveal Melanoma
Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
Single arm study with dose escalation Phase Ib cohort followed by a Phase II cohort. PAC-1 (PO) will be given daily on Days 1 through 21 of each cycle (28-day cycle).
- Trial name
- NCT04589832
- Testing
- PAC-1, Entrectinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Arkadiusz Z. Dudek, MD
Uveal Melanoma
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
A phase Ib dose-escalation study of the AEB071 and MEK162 combination in adult patients with confirmed metastatic uveal melanoma.
- Trial name
- NCT01801358
- Testing
- AEB071, MEK162
- Where
- 7 sites in United States, France and 4 more
- Volunteers
- 38 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Metastatic Uveal Melanoma
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or…
- Trial name
- NCT05987332
- Testing
- IDE196, Crizotinib, Pembrolizumab
- Where
- 68 sites in United States, Australia and 11 more
- Volunteers
- 420 people
- Sponsor
- IDEAYA Biosciences
Ocular Melanoma
Study of Metastatic Ocular Melanoma
This study evaluates treatment with combination versus monotherapy for patients with metastatic ocular melanoma.
- Trial name
- NCT00168870
- Testing
- Gemcitabine, Treosulfan
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Charite University, Berlin, Germany
Uveal Melanoma
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
- Trial name
- NCT07804186
- Testing
- Darovasertib, Crizotinib (Xalkori)
- Where
- 13 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- IDEAYA Biosciences
Uveal Melanoma
Neoadjuvant Darovasertib in Primary Uveal Melanoma
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
- Trial name
- NCT07015190
- Testing
- Darovasertib, Primary Local Therapy
- Where
- 94 sites in United States, Australia and 19 more
- Volunteers
- 520 people
- Sponsor
- IDEAYA Biosciences
Melanoma (Skin), Melanoma Stage IV
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
The study hypothesis is that new imaging agents [203Pb]VMT01 and [68Ga]VMT02 can be safely used in humans without independent biological effect and can be used to image melanoma tumors expressing the melanocortin sub-type 1…
- Conditions
- Melanoma (Skin), Melanoma Stage IV, Melanoma, Uveal, Melanoma, Mucosal
- Trial name
- TIMAR1 (NCT04904120)
- Testing
- [203Pb]VMT01, [68Ga]VMT02
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Perspective Therapeutics
Cutaneous Melanoma, Mucosal Melanoma
Neoadjuvant and Adjuvant Checkpoint Blockade
This randomized phase II trial studies how well nivolumab with or without ipilimumab or relatlimab before surgery works in treating patients with stage IIIB-IV melanoma that can be removed by surgery.
- Conditions
- Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7
- Trial name
- NCT02519322
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
This phase Ib trial studies the side effects and best dose of autologous CD8 positive (+) SLC45A2-specific T lymphocytes when given together with cyclophosphamide, aldesleukin, and ipilimumab, and to see how well they work in…
- Trial name
- NCT03068624
- Testing
- Aldesleukin, Autologous CD8+ SLC45A2-specific T Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Uveal Melanoma
Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)
Because we suspect that the benefit of anti-PD-1 in metastatic UM patients could vary according to previous exposure to Tebentafusp (better efficacy of anti-PD-1 after Tebentafusp), the combination of pembrolizumab and lenvatinib…
- Trial name
- PLUME (NCT05282901)
- Testing
- Pembrolizumab 25 MG/1 ML Intravenous Solution
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Institut Curie
Uveal Melanoma, Ocular Melanoma
Study in Subjects With Small Primary Choroidal Melanoma
The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with…
- Conditions
- Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
- Trial name
- NCT03052127
- Testing
- Light-activated AU-011, Laser Activation
- Where
- 13 sites in United States
- Volunteers
- 57 people
- Sponsor
- Aura Biosciences